NeoGenomics launched PTEN IHC CDx, described as the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma. The FDA approval and product debut are a meaningful regulatory milestone that could support adoption in prostate cancer diagnostics.
NeoGenomics launched PTEN IHC CDx, described as the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma. The FDA approval and product debut are a meaningful regulatory milestone that could support adoption in prostate cancer diagnostics.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.50
Ticker Sentiment
